Sharma Kaushal, Syeda Safia, Shah Sanket M, Kori Sonali A, Shetty Pratiksha, Kazi Saniya, Khaiterpal Archana, Choudhary Aasiya, Pathak Sarang, Ahmed Syed
Business Development and Strategy, TechInvention Lifecare Private Limited, Mumbai, India.
Strategic Medical Affairs, Techinvention Lifecare Private Limited, Mumbai, India.
Hum Vaccin Immunother. 2025 Dec;21(1):2483043. doi: 10.1080/21645515.2025.2483043. Epub 2025 Mar 25.
The COVID-19 pandemic revealed global disparities in accessing medical countermeasures, as high-income countries prioritised their own interests while disregarding low- and middle-income countries. Despite global efforts to ensure an equitable pandemic response, these initiatives largely failed to achieve their objectives for LMICs due to systemic inequalities. This review critically examines these disparities, identifying that excessive stockpiling by HICs, fragmented international coordination, inadequate research and manufacturing capacity, restricted access to emergency research funding, intellectual property constraints, unequal participation in clinical trials, and inadequate regulatory harmonisation collectively hinder LMICs ability to respond effectively. By analysing diverse case scenarios and global response strategies, all plausible key shortcomings that contributed to the failure of coordinated pandemic preparedness were highlighted. Based on these insights, actionable strategies are proposed to address these gaps in LMICs so as to ensure affordability, accessibility, and equitable distribution of vaccines, diagnostics, and biotherapeutics in future public health emergencies, strengthening global biosecurity.
新冠疫情暴露了全球在获取医疗应对措施方面的差距,因为高收入国家优先考虑自身利益,而忽视了低收入和中等收入国家。尽管全球努力确保公平应对疫情,但由于系统性不平等,这些举措在很大程度上未能实现其对低收入和中等收入国家的目标。本综述批判性地审视了这些差距,发现高收入国家过度囤货、国际协调碎片化、研究和制造能力不足、紧急研究资金获取受限、知识产权限制、临床试验参与不平等以及监管协调不足共同阻碍了低收入和中等收入国家有效应对的能力。通过分析各种案例情景和全球应对策略,突出了导致协同大流行防范失败的所有可能的关键缺陷。基于这些见解,提出了可采取行动的策略来弥补低收入和中等收入国家的这些差距,以便在未来公共卫生紧急事件中确保疫苗、诊断工具和生物治疗药物的可负担性、可及性和公平分配,加强全球生物安全。